Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebo-controlled trial (EASE-1)

Diabetes, Obesity and Metabolism

Volumn 17, Issue 10, 2015, Pages 928-935

  Pieber, T R ^a   Famulla, S ^b   Eilbracht, J ^c   Cescutti, J ^d   Soleymanlou, N ^e   Johansen, O E ^f   Woerle, H J ^c   Broedl, U C ^c   Kaspers, S ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Profil   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM   (France)

^e BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^f Boehringer Ingelheim Norway KS   (Norway)

Author keywords

Pharmacodynamics; Pharmacology; SGLT2 inhibitor; Type 1 diabetes

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; URINARY TRACT INFECTION; AUSTRIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; GERMANY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; URINE; WEIGHT REDUCTION;

ADULT; AUSTRIA; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GLUCOSIDES; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84942258219     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12494     Document Type: Article

References (26)

1. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014; 37(Suppl. 1): S14-80.
2. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes 2010; 59: 2333-2339.
3. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007; 9: 799-812.
4. Nathan DM, Cleary PA, Backlund JY etal. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
5. Weinstock RS, Xing D, Maahs DM etal. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013; 98: 3411-3419.
6. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115: 1859-1868.
7. de Ferranti SD, de Boer IH, Fonseca V etal. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014; 37: 2843-2863.
8. Nordwall M, Abrahamsson M, Dhir M etal. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care 2015; 38: 308-315.
9. Laing SP, Swerdlow AJ, Slater SD etal. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 2003; 46: 760-765.
10. Grempler R, Thomas L, Eckhardt M etal. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
11. Heise T, Seewaldt-Becker E, Macha S etal. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 613-621.
12. Perkins BA, Cherney DZ, Partridge H etal. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014; 37: 1480-1483.
13. Haering H-U, Merker L, Seewaldt-Becker E etal. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-1659.
14. Haering H-U, Merker L, Seewaldt-Becker E etal. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
15. Kovacs CS, Seshiah V, Swallow R etal. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-158.
16. Roden M, Weng J, Eilbracht J etal. Empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator. Lancet Diabetes Endocrinol 2013; 1: 208-219.
17. Rosenstock J, Jelaska A, Frappin G etal. Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes. Diabetes Care 2014; 37: 1815-1823.
18. Rosenstock J, Jelaska A, Zeller C et al. Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17: 936-948.
19. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 2015; 66: 255-270.
20. Fidler C, Elmelund CT, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011; 14: 646-655.
21. Awoniyi O, Rehman R, Dagogo-Jack S. Hypoglycemia in patients with type 1 diabetes: epidemiology, pathogenesis, and prevention. Curr Diab Rep 2013; 13: 669-678.
22. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-948.
23. Ridderstrale M, Andersen KR, Zeller C etal. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700.
24. Ferrannini E, Muscelli E, Frascerra S etal. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508.
25. Cherney DZ, Perkins BA, Soleymanlou N etal. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597.
26. Henry RR, Rosenstock J, Edelman S etal. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38: 412-419.